TITLE

B Experimental therapeutics: preclinical

PUB. DATE
October 2008
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Oct2008, Vol. 79 Issue 0, pA7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
47628922

 

Related Articles

  • Immunotherapy with Peptides in Systemic Lupus Erythematosus. La Cava, Antonio // Current Medicinal Chemistry;Apr2009, Vol. 16 Issue 12, p1482 

    In systemic lupus erythematosus (SLE), the interaction between hyperactive T cells and B cells causes a dysregulated production of autoantibodies that can lead to tissue damage and impaired organ function. Studies on the modalities of communication between T and B cells have led to the design of...

  • Antitumor Efficacy Testing in Rodents. Hollingshead, Melinda G. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p100 

    The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, often guide the selection of agents for clinical...

  • American Thoracic Society Intl Conference: Inhibition of PBEF is a possible therapeutic target for pulmonary hypertension.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article presents information on a preclinical study according to which inhibition of pre-B Cell Colony-Enhancing Factor can be a potential therapeutic target in preventing pulmonary hypertension.

  • Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment. Vera, Renzo; Lamberti, MarĂ­a; Rivarola, Viviana; Rumie Vittar, Natalia // Tumor Biology;Dec2015, Vol. 36 Issue 12, p9127 

    Melanoma is among the most aggressive and treatment-resistant human skin cancer. Photodynamic therapy (PDT), a minimally invasive therapeutic modality, is a promising approach to treating melanoma. It combines a non-toxic photoactivatable drug called photosensitizer with harmless visible light...

  • Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus. Kim, Young-In; DeVincenzo, John P.; Jones, Bart G.; Rudraraju, Rajeev; Harrison, Lisa; Meyers, Rachel; Cehelsky, Jeff; Alvarez, Rene; Hurwitz, Julia L. // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection...

  • Encouraging preclinical results for prostate cancer agent.  // Westchester County Business Journal;10/7/2002, Vol. 41 Issue 40, p22 

    Announces the encouraging preclinical results with experimental drug for prostate cancer by PSMA Development Company LLC in Princeton, New Jersey. Function of experimental drug; Effectiveness of drug; Plans of the company to initiate clinical studies of therapeutic prostate cancer vaccines.

  • Are We There Yet?  // BioWorld Today;4/6/2011, Vol. 22 Issue 66, p8 

    The article focuses on the preclinical data presented by Semafore Pharmaceuticals Inc. at the 2011 meeting of the American Association for Cancer Research on the therapeutic effects of lead candidate SF1126 in two diffuse large B-cell lymphoma cell lines.

  • Syndexa Pharmaceuticals Expands Series B1 Financing Round with Investment by MP Healthcare Venture Management.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article presents information on the investment and financial support received by Syndexa Pharmaceuticals Corp. from MP Healthcare Venture Management. The expansion of the Series B1 Financing Round of Syndexa Pharmaceuticals enables the progress of preclinical development of Endoplasmic...

  • Involvement of Tachykinins in Intestinal Inflammation. Evangelista, S. // Current Pharmaceutical Design;Jan2001, Vol. 7 Issue 1, p19 

    The tachykinins, substance P, neurokinin A and neurokinin B are small peptides expressed in the extrinsic primary afferent nerve fibers and enteric neurons of the gut. Tachykinins exert a variety of biological actions mediated by three distinct receptors, termed NK 1 , NK 2 and NK 3 , and at the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;12/13/2013, Vol. 24 Issue 239, p10 

    The article offers news briefs in the biopharmaceutics industry in 2013. Ico Therapeutics Inc.'s s oral amphotericin B is entering in vitro testing with study partners in Montreal to explore the role of the formulation in targeting latent HIV reservoirs. Therapeutics Inc. is set to design...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics